Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Surmodics jumps amid pre-trial hearing in FTC′s suit to block sale to GTCR (SeekingAlpha) +++ SURMODICS Aktie +6,25%

BIO-RAD A Aktie

 >BIO-RAD A Aktienkurs 
224.85 EUR    (Tradegate)
Ask: 225.4 EUR / 50 Stück
Bid: 224.3 EUR / 50 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
BIO-RAD A Aktie über LYNX handeln
>BIO-RAD A Performance
1 Woche: +6,1%
1 Monat: +10,3%
3 Monate: +5,4%
6 Monate: -33,5%
1 Jahr: -23,0%
laufendes Jahr: -28,4%
>BIO-RAD A Aktie
Name:  BIO-RAD LABS INC.DL-,0001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US0905722072 / 865406
Symbol/ Ticker:  BUWA (Frankfurt) / BIO (NYSE)
Kürzel:  FRA:BUWA, ETR:BUWA, BUWA:GR, NYSE:BIO
Index:  -
Webseite:  https://www.bio-rad.com/
Marktkapitalisierung:  6123.95 Mio. EUR
Umsatz:  2164.21 Mio. EUR
EBITDA:  451.02 Mio. EUR
Gewinn je Aktie:  -64.87 EUR
Schulden:  1166.38 Mio. EUR
Liquide Mittel:  445.17 Mio. EUR
Umsatz-/ Gewinnwachstum:  -2.72% / -569.55%
KGV/ KGV lG:  - / 30.6
KUV/ KBV/ PEG:  2.87 / 1.01 / -0.01
Gewinnm./ Eigenkapitalr.:  -85.16% / -27.51%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  BIO-RAD A, BIO RAD, BIO-RAD
Letzte Datenerhebung:  26.07.25
>BIO-RAD A Eigentümer
Aktien: 22.14 Mio. St.
f.h. Aktien: 18.66 Mio. St.
Insider Eigner: 16.14%
Instit. Eigner: 93.05%
>BIO-RAD A Peer Group

 
17.07.25 - 22:21
Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025 (Business Wire)
 
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2025 on Thursday, July 31, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call, as well as a supplemental earnings presentation, will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics mark...
14.07.25 - 16:00
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms (Zacks)
 
BIO surges 4% as the Stilla acquisition fuels the launch of four ddPCR systems, expanding to 400K+ assay offerings....
02.05.25 - 15:15
BIO Beats on Q1 Earnings, Lowers ′25 View, Stock Up in Aftermarket (Zacks)
 
Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market....
02.05.25 - 04:42
Bio-rad outlines updated 2025 guidance amid academic and macro challenges (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.05.25 - 01:00
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates (Zacks)
 
Bio-Rad (BIO) delivered earnings and revenue surprises of 46.82% and 0.05%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...
30.04.25 - 23:21
Bio-Rad Labs Q1 2025 Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
23.04.25 - 12:03
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types (GlobeNewswire EN)
 
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology...
15.04.25 - 22:21
Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 (Business Wire)
 
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2025 on Thursday, May 1, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:30 PM Pacific Time (5:30 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates ...
03.04.25 - 16:45
Should You Continue to Hold Bio-Rad Stock in Your Portfolio? (Zacks)
 
BIO continues to attract investors' attention due to its robust performance in the ddPCR platform....
19.03.25 - 00:01
Insiderhandel: EVP, GBL Commercial Operations verkauft Aktien von Bio-Rad Laboratories im Wert von 741184 USD (Insiderkauf)
 
Crowley, Michael - Vorstand - Tag der Transaktion: 2025-03-14...
18.02.25 - 15:15
BIO Stock Might Rise Following the Offer to Acquire Stilla (Zacks)
 
Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio....
14.02.25 - 21:15
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket (Zacks)
 
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products....
14.02.25 - 05:48
Bio-Rad targets 1.5%-3.5% revenue growth in 2025 amid operational improvements and new acquisitions (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.02.25 - 01:00
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates (Zacks)
 
Bio-Rad (BIO) delivered earnings and revenue surprises of -1.02% and 1.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...
13.02.25 - 23:00
Bio-Rad Labs Non-GAAP EPS of $2.90 beats by $0.02, revenue of $667.5M misses by $12.25M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.02.25 - 22:30
Bio-Rad offers to acquire digital PCR developer Stilla Technologies (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.02.25 - 22:27
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results (Business Wire)
 
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2024. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, commented: “Bio-Rad demonstrated resilience and adaptability in 2024. While the biopharma headwinds dampened our Life Science segment results, our Clinical Diagnostics business returned to a more normalized growth rate, and our ongoing transformation initiatives and diligent cost management helped improve our gross margins.” Mr. Schwartz continued: “We begin 2025 in a strong position and remain committed to advancing our transformation, margin expansion, commercial excellence, and long-term shareholder value creation. The anticipated acquisition of digital PCR developer Stilla Technologies furthers our planned transformation as it would support our customers' increasingly diverse r...
06.02.25 - 17:30
Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline (Zacks)
 
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
27.01.25 - 23:03
Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025 (Business Wire)
 
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year of 2024 on Thursday, February 13, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year. About Bio-Rad Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bi...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Herr wird denen entgegenkommen, die verstehen, in den Tag hinein zu leben, immer ihre Pflicht tun, mit Ruhe, Würde und Geduld, ohne sich den Kopf heiß zu machen wegen der Dinge, die morgen oder in Zukunft geschehen können. - Papst Johannes XXIII.
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!